Dapagliflozin a new approach in the treating patients with heart failure: DAPA – HF Trial MD Editorial Team14 Feb 2022 9:00 AM ISTCardiac health is very important as its one of the vital organs. Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an...
Diabetic nephropathy effectively treated by Dapagliflozin: DAPA-CKD Trial MD Editorial Team12 Feb 2022 9:00 AM ISTDiabetes is a chronic disease that is the leading cause of kidney failure, accounting for 44% percent of new cases. Diabetic nephropathy is a serious...
DAPA CKD Trial: Dapaglifloxin to improve diabetic nephropathy Dr. Nandita Mohan11 Feb 2022 6:56 PM IST Diabetic nephropathy is a serious complication of type 1 diabetes and type 2 diabetes. It's also called diabetic kidney disease. In the United...
Dapagliflozin appears beneficial at various levels of Heart Failure in HFrEF patients: Study Dr. Shravani Dali10 Dec 2021 9:00 AM ISTDapagliflozin appears beneficial at various levels of Heart Failure with Reduced Ejection Fraction, according to a study published in the ...
Dapagliflozin improves kidney function in patients with diabetes patients with CKD: Lancet Medha Baranwal1 Nov 2021 9:00 AM ISTDelhi: Dapagliflozin compared with placebo significantly improves the rate of decline in kidney function in patients with chronic kidney disease...
Dapagliflozin reduces albuminuria in CKD patients with or without diabetes: Lancet study Medha Baranwal7 Oct 2021 10:30 AM ISTUSA: A prespecified analysis from the DAPA-CKD trial has found that the SGLT2 inhibitor dapagliflozin significantly reduces albuminuria in patients...
Dapagliflozin, saxagliptin combo bests glimepiride for controlling blood sugar in diabetes: Study Medha Baranwal30 Sept 2021 12:45 PM ISTUSA: The combo of dapagliflozin+saxagliptin+metformin was associated with better blood sugar control, efficacy, and metabolic benefits than...
Dapagliflozin relieves symptoms, physical limitations in HFpEF patients: PRESERVED-HF trial Medha Baranwal25 Sept 2021 9:00 AM ISTUSA: Dapagliflozin improves physical limitations and symptoms in patients having heart failure with preserved ejection fraction (HFpEF) within a...
Dapagliflozin reduces risk of sudden cardiac death, ventricular arrhythmia in HFrEF patients: Study Medha Baranwal6 Sept 2021 9:00 AM ISTUK: A recent study has found that dapagliflozin when added to conventional therapy in HFrEF patients reduces the risk of cardiac arrest, any serious...
NPPA fixes retail price of 19 formulations including Metformin, Dapagliflozin, Details Medical Dialogues Team27 Aug 2021 1:45 PM ISTNew Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India,...
Dapagliflozin a cost-effective adjunct therapy for chronic HFrEF: Study Dr. Shravani Dali21 Aug 2021 6:15 AM ISTDapagliflozin is an economical adjunct therapy to usual care for the management of chronic heart failure and reduced ejection fraction (HFrEF),...
Dapagliflozin reduces risk for hyperkalemia in HFrEF patients treated with MRAs: Study Dr. Shravani Dali20 Aug 2021 9:00 AM ISTDapagliflozin Reduces Hyperkalemia Risk in Heart Failure and reduced ejection fraction (HFrEF) in patients treated with mineralocorticoid receptor...
